Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects

M. Norelli, M. Casucci, C. Bonini, A. Bondanza

Research output: Contribution to journalArticlepeer-review

Abstract

Adoptive cell transfer of T cells genetically modified with tumor-reactive chimeric antigen receptors (CARs) is a rapidly emerging field in oncology, which in preliminary clinical trials has already shown striking antitumor efficacy. Despite these premises, there are still a number of open issues related to CAR-T cells, spanning from their exact mechanism of action (pharmacodynamics), to the factors associated with their in vivo persistence (pharmacokinetics), and, finally, to the relative contribution of each of the two in determining the antitumor effects and accompanying toxicities. In light of the unprecedented curative potential of CAR-T cells and of their predicted wide availability in the next few years, in this review we will summarize the current knowledge on the clinical pharmacology aspects of what is anticipated to be a brand new class of biopharmaceuticals to join the therapeutic armamentarium of cancer doctors.

Original languageEnglish
Pages (from-to)90-100
Number of pages11
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1865
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Keywords

  • Adoptive cell transfer
  • Cancer immunotherapy
  • Clinical results
  • Genetically modified T cells
  • Pharmacokinetics/pharmacodynamics
  • Toxicities

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Fingerprint

Dive into the research topics of 'Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects'. Together they form a unique fingerprint.

Cite this